AstraZeneca's AZD7442 Trial Showed Reduced Risk of Developing Severe Covid-19
October 11 2021 - 2:44AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Monday that high-level results from the
AZD7442 long-acting antibody's Phase 3 trial showed a statistically
significant reduction in the risk of developing severe Covid-19 or
death.
The U.K. pharmaceutical company said the trial met its primary
endpoint, and that AZD7442 was the only long-acting antibody
combination shown to both prevent and treat Covid-19.
"These important results for AZD7442... add to the growing body
of evidence for use of this therapy in both prevention and
treatment of Covid-19. An early intervention with our antibody can
give a significant reduction in progression to severe disease, with
continued protection for more than six months," the company
said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
October 11, 2021 02:29 ET (06:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024